Abeona Therapeutics Inc. · NASDAQ:ABEO
Abeona Therapeutics — Investor Presentation (June 2026)
22 slides from Abeona Therapeutics's investor presentation, Jun 10, 2026
Slide 1: Investor Presentation June 2026
i: “Yi Ab eona’ THERAPEUTICS INVESTOR PRESENTATION June 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempt
Slide 3: Abeona, a Commercial-Stage, Cell and Gene Therapy Company
Anchored by ZEVASKYN®, an FDA-approved, ex-vivo autologous gene therapy for RDEB with durable clinical benefit from a one-time application. i Combination of in-house cGMP manufacturing, regulatory expertise, and a lean commercial model. Abeona, a Commercial-Stage, Cell and Gene Therapy Company With
Slide 4: Pipeline
Pipeline PRECLINICAL PHASE 1/2 PHASE 3 APPROVED —_ zevaskyn” (prademagene zamikeracel) gene-moified cellular sheets PSMA-SIR-T* Advanced Prostate Cancer UXx111** ‘ Sanfilippo syndrome type A (MPS IIIA) ultrageny TSHA-102*** Rett syndrome Taysha Undisclosed (AAV204 capsid)**** Range of prevalent & ra
Slide 5: ZEVASKYN for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
ZEVASKYN® for Recessive Dystrophic Epidermolysis Bullosa (RDEB) (prademagen gene-modified cellular sheets Va Differentiated profile with transformational potential Demonstrated wound healing and pain reduction Sustained clinical benefit and no treatment-related serious AEs over 12 years of follow-up
Slide 6: Recessive Dystrophic Epidermolysis Bullosa (RDEB) Overview
Recessive Dystrophic Epidermolysis Bullosa (RDEB) Overview Rare and debilitating monogenic skin disease Caused by mutations in both copies of COL 7A1 gene, resulting in lack of collagen VII, a protein necessary to keep skin intact Leads to fragile skin that blisters easily RDEB wounds can lead to se
Slide 7: First and Only Gene Therapy Made From Patients' Own Skin Cells to Treat Wounds in Children and Adults with RDEB
First and Only Gene Therapy Made From Patients’ Own Skin Cells to Treat Wounds in Children and Adults with RDEB a zevaskyn’ (prademagene zamikeracel) gene-modified cellular sheets ¢ Single treatment application ° Covers large wound areas ¢ Provides years of healing & pain relief ES I< Geovanna, a ZE
Slide 8: ZEVASKYN: Ex-Vivo Autologous Gene-Corrected Breakthrough Therapy for Large and Chronic Wounds
ZEVASKYN®: Ex-Vivo Autologous Gene-Corrected Breakthrough Therapy for Large and Chronic Wounds ZEVASKYN READY FOR PATIENTS Two 8 mm skin biopsies @ shipped to Abeona, produces Transprantation oN up to 12 ~40 cm? sheets Collagen Type Vil Gene-corrected Epidermal Sheet Continued ZEVASKYN Restores cell
Slide 9: Up to 12 ZEVASKYN Sheets Can Be Applied in One Surgical Session
Up to 12 ZEVASKYN® Sheets Can Be Applied in One Surgical Session ZEVASKYN sheets can be joined together to treat larger wounds on your front, back, or sides, or used Two 0.8cm = up to12 individually for smaller wounds punch biopsies ZEVASKYN® sheets ‘About the size of a credit card, ZEVASKYN cellula
Slide 10: Durable wound healing and reduction in pain and itch
Durable wound healing and reduction in pain and itch * Wound healing and reduction of pain and itch seen with treatment, even in tough large, chronic RDEB wounds * Sustained wound healing and long- term safety Favorable long-term safety profile * Noserious adverse events (SAEs) related to ZEVASKYN (
Slide 11: Significant Wound Healing and Reduction in Pain Reported With ZEVASKYN
Significant Wound Healing and Reduction in Pain‘ Reported With ZEVASKYN® Wound healing from baseline at Week 24 Co-primary endpoint P<0.0001 81.4% [ P<0.0001 65.1% bs >50% Healing >75% Healing Bpz-cel m Control 16.3% Complete Healing* Mean pain reduction & oe Pain reduction from baseline at Week 24
Slide 12: Example RDEB Wounds Before and After ZEVASKYN Treatment
Example RDEB Wounds Before and After ZEVASKYN® Treatment BEFORE AFTER ZEVASKYN BEFORE AFTER ZEVASKYN Left thigh Abeona THERAPEUTICS
Slide 13: Multi-Year Wound Healing and Pain Reduction After Single Application of ZEVASKYN in Phase 1/2a study
Multi-Year Wound Healing and Pain Reduction After Single Application of ZEVASKYN¢® in Phase 1/2a study % treated wounds with % treated wounds with pain 250% or =75% healing (n/N) (20/38) 53% 250% m275% ) (2738) pe 5% (0/26) (0/15) (0/15) (0/5) 0% om 0% 0% c 6mo ty 2v 3y ay 5Y oy Nv 8y Baseline tay 2
Slide 14: Multi-Year Wound Healing After One-Time Zevaskyn Application
Multi-Year Wound Healing After One-Time Zevaskyn Application “iil Upper back Upper back Upper back Upper back Abeona THERAPEUTICS
Slide 15: Presentation at SID2026 on Sustained Wound Healing and Long-term Safety
Presentation at SID2026 on Sustained Wound Healing and Long-term Safety: 12-year Case Report and 5-vear Phase 3 Data (below) and 12-year Case Report Wound #: Location Basolino Day-26toDay} Month6 Year1 -1 | Subject #1 Right Upper Arm Subject #2 Left Leg, Anterior Subject #3 LeftThigh Lateral Individ
Slide 16: Significant US Commercial Opportunity for ZEVASKYN
Significant US Commercial Opportunity for ZEVASKYN® ~1,300 US DEB patients}; ~750 RDEB ZEVASKYN-eligible patients Anticipate average 2 treatment cycles per patient to cover impacted body areas (~1,500 treatment opportunities) —_ zevaskyn”™ $3.1M WAC per each treatment; (pradem gen ani el) >$4B cumul
Slide 17: Expanded QTC Network Enhances Patient Access
Expanded QTC Network Enhances Patient Access / \ ©) ann & Robert H. Lurie NewYork. \ i hildren’s Hospital of Chicago" 71 Presbyterian Stanford a Columbia University <] : \ Irving Medical Center Children’s Health” hildren’s Hospital Colorado’ Children’s Hospital of Philadelphia’ Abeona THERAPEUTICS
Slide 18: Leveraging Cell Therapy Core Competencies to Advance A Novel Pipeline
Slide 19: PSMA SIR-T Has the Potential To Unlock Cell Therapy For Prostate Cancer
PSMA SIR-T™ Has the Potential To Unlock Cell Therapy For Prostate Cancer Patients With A High Unmet Need * PSMA isa validated target in prostate cancer, but CAR-Ts and other immunotherapies targeting PSMA have failed to deliver durable efficacy and acceptable safety profiles * PSMA SIR-T™ is a radic
Slide 20: Synthetic Immune Receptor Combines the Best of CAR and TCR
Synthetic Immune Receptor Combines the Best of CAR and TCR * Designed to overcome the fundamental limitations of CARs SIR-T v * Retains the full signaling strength, complexity, and physiological regulation of a TCR * Exceptional in vivo responses vs. CAR T cells in preclinical models, with less infl
Slide 21: PSMA-SIR-T Demonstrated Better Tumor Remission and Durability
PSMA-SIR-T™ Demonstrated Better Tumor Remission and Durability Compared to CAR Controls with the Same PSMA Binding Domain oa ~~ om me. » — PBS — ULT = PSMA-scFv-BBz-CAR —— PSMA-svH-BBz-CAR PSMA-SIR 20 40 60 Days after T cell injection Percent survival ee a ae ae -~ =e oe oo a} -9 a - IND Submission
Slide 22: Significant support of ZEVASKYN from the RDEB community and commercial launch on positive trajectory
Significant support of ZEVASKYN® from the RDEB community and commercial launch on positive trajectory $8.7M* net product revenue Q1 2026, an increase of $6.3M Quarter over Quarter Pipeline expansion into solid tumor oncology with PSMA program, a multi- billion-dollar opportunity
Abeona Therapeutics — Investor Presentation (June 2026) on 6ix